Hydroxyzine Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Dosage Form (Tablets, Capsules, Injection, Syrup), By Indication Type (Histamine-mediated pruritus, Utricaria, Atopic contact dermatitis), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.03 Billion
CAGR (2026-2031)	6.58%
Fastest Growing Segment	Tablets
Largest Market	North America
Market Size (2031)	USD 1.51 Billion

Market Overview

The Global Hydroxyzine Market will grow from USD 1.03 Billion in 2025 to USD 1.51 Billion by 2031 at a 6.58% CAGR. Hydroxyzine is a piperazine-derivative antihistamine exhibiting anticholinergic, anxiolytic, and sedative properties, primarily indicated for the symptomatic management of anxiety and pruritus associated with dermatological conditions. The global market is structurally supported by the rising prevalence of generalized anxiety disorders and the sustained clinical requirement for non-benzodiazepine sedative options in preoperative and acute care settings. These fundamental drivers are distinct from temporary adoption patterns, representing a consistent therapeutic demand across both pediatric and geriatric patient demographics.

Despite this robust utility, the market encounters significant impediments regarding supply chain reliability and manufacturing consistency. Regulatory pressures and the consolidation of generic producers often precipitate inventory deficits which disrupt continuous product availability. According to the American Society of Health-System Pharmacists, in 2024, the healthcare sector reported a record peak of 323 active drug shortages during the first quarter, highlighting the systemic manufacturing volatility that frequently impacts the supply of essential generic injectables including hydroxyzine.

Key Market Drivers

The escalating prevalence of anxiety and stress-related disorders serves as a primary catalyst for the hydroxyzine market, particularly given the clinical shift toward non-habit-forming pharmacotherapy. Hydroxyzine is increasingly favored over benzodiazepines for the symptomatic relief of anxiety and tension due to its lower abuse potential and established safety profile. This trend is amplified by a global rise in self-reported stress levels, which necessitates accessible pharmacological interventions. According to the American Psychiatric Association, May 2024, in the '2024 Mental Health Poll', 43% of adults reported feeling more anxious than they did the previous year, highlighting a substantial patient pool requiring anxiolytic management. This surge in mental health acuity directly correlates with higher prescription volumes for hydroxyzine as a frontline or adjunctive treatment in both primary care and psychiatric settings.

Simultaneously, the rising incidence of allergic dermatitis and chronic pruritus sustains the demand for hydroxyzine, utilized for its histamine H1-antagonist capabilities to mitigate severe itching. The drug remains a staple in dermatology for managing conditions where pruritus disrupts sleep or quality of life. According to the Asthma and Allergy Foundation of America, March 2024, in the '2024 Allergy Capitals' report, approximately 100 million people in the U.S. live with various types of allergies, many of which manifest as skin conditions requiring antihistamines. Consequently, the market is bolstered by the consistent consumption of generic formulations to treat these chronic ailments. According to the Association for Accessible Medicines, in 2024, generic medicines accounted for 90% of all prescriptions dispensed in the United States, reflecting the critical role of affordable therapeutics like hydroxyzine in maintaining widespread market reach.

Download Free Sample Report

Key Market Challenges

Supply chain reliability and manufacturing consistency represent the primary impediments limiting the expansion of the Global Hydroxyzine Market. As a mature generic pharmaceutical, hydroxyzine is subject to intense pricing pressures that have forced market consolidation, leaving global production dependent on a limited number of manufacturing facilities. When these few producers face regulatory compliance issues, quality control failures, or raw material bottlenecks, the market lacks the redundancy required to absorb the disruption. This structural fragility directly hampers growth by physically capping the volume of saleable inventory, preventing suppliers from fulfilling the rising clinical orders for anxiety and dermatological treatments despite robust demand.

The inability to guarantee consistent product availability creates revenue volatility and deters healthcare providers from relying on hydroxyzine for long-term therapeutic protocols, potentially shifting preference toward more readily available alternatives. This constraint is not merely a temporary fluctuation but a sustained systemic issue. According to the American Society of Health-System Pharmacists, in 2025, the healthcare sector continued to navigate a restricted supply environment with 270 active drug shortages reported as of April, indicating that manufacturing instability remains a critical barrier to market continuity. This persistent deficit in supply chain resilience effectively creates a ceiling on the market’s realizable value, as manufacturers cannot generate revenue from demand they are unable to supply.

Key Market Trends

The Expansion of Off-Label Veterinary Applications is diversifying revenue streams as hydroxyzine becomes integral for treating canine atopic dermatitis and anxiety. This trend drives the production of specialized compounded medications, such as flavored chews, which address unique dosing challenges in companion animals. The market is bolstered by a steadily increasing volume of potential veterinary patients, ensuring consistent consumption independent of human clinical patterns. According to the American Veterinary Medical Association, December 2024, in the '2024 Pet Ownership and Demographics Sourcebook', the U.S. dog population reached 89.7 million in 2024, securing a vast demand for these antihistamines. This veterinary focus effectively creates a parallel market vertical insulated from the supply chain pressures affecting human generic injectables.

Concurrently, the Development of Sustained-Release Dosage Forms represents a pivotal shift toward modernizing this mature therapeutic class. To combat compliance issues caused by frequent dosing, manufacturers are prioritizing controlled-release technologies that stabilize drug delivery and mitigate sedative side effects. This innovation allows for repositioning hydroxyzine as a user-friendly maintenance therapy rather than just an acute intervention. According to Dr. Reddy's Laboratories, May 2025, in the study 'From lab-to-clinic with model informed formulation development: a case study of hydroxyzine SR tablets', researchers validated a new formulation that significantly reduces peak plasma concentration-related sedation. By minimizing adverse effects, these advanced dosage forms offer a competitive edge over standard generics, unlocking new value in chronic pruritus management.

Segmental Insights

The Tablets segment is currently identified as the fastest-growing category within the Global Hydroxyzine Market, driven by a distinct preference for oral solid dosage forms in outpatient settings. This expansion is primarily underpinned by the formulation's superior physical stability, extended shelf life, and ease of transport, which offer significant logistical advantages over liquid or injectable alternatives. Furthermore, tablets ensure high dosage precision and facilitate convenient self-administration, factors that are critical for maintaining patient adherence during the long-term management of chronic anxiety and allergic dermatoses. These practical benefits continue to accelerate the adoption of hydroxyzine tablets globally.

Regional Insights

North America holds a leading position in the global hydroxyzine market, driven primarily by the rising prevalence of anxiety disorders and pruritus within the United States and Canada. The region benefits from a well-structured healthcare system that facilitates easy access to prescription medications. Additionally, the United States Food and Drug Administration maintains established approvals for hydroxyzine as a treatment for anxiety and tension, reinforcing clinical confidence in the drug. This regulatory clarity, combined with the presence of key pharmaceutical manufacturers, sustains strong market demand throughout the region.

Recent Developments

• In May 2024, Apozeal Pharmaceuticals Inc. announced the launch of its Hydroxyzine Hydrochloride Oral Solution, USP 10 mg/5 mL, in the United States market. This new product, which received FDA approval, was introduced to provide a high-quality, affordable treatment option for patients suffering from anxiety and pruritus. The company highlighted that the solution is indicated for the symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states. The launch marked a significant expansion of Apozeal's portfolio, with the product being manufactured at its facility in Levittown, Pennsylvania.
• In April 2024, the U.S. Food and Drug Administration (FDA) issued a determination regarding Vistaril (hydroxyzine pamoate) Oral Suspension, 25 mg/5 mL, which is held by Pfizer Inc. The agency concluded that the drug was not withdrawn from sale for reasons of safety or effectiveness. This regulatory decision was significant for the market as it cleared the pathway for the approval of Abbreviated New Drug Applications (ANDAs) for generic versions of the suspension. The FDA stated that it would continue to list the product in the "Discontinued Drug Product List" section of the Orange Book, while allowing new generic competitors to enter the market if they meet legal requirements.
• In March 2024, the United States Pharmacopeia (USP) published a Revision Bulletin for the Hydroxyzine Hydrochloride Tablets monograph, which became official in April 2024. This technical development was a result of the Small Molecules 4 Expert Committee's review, which added "Dissolution Test 3" to the standard specifications. The revision was implemented to accommodate FDA-approved drug products that require different dissolution conditions or tolerances than the existing tests. This update provided crucial compliance guidelines for pharmaceutical manufacturers producing hydroxyzine hydrochloride tablets, ensuring that their products meet the necessary quality and performance standards for the US market.
• In January 2024, Rising Pharmaceuticals made its Hydroxyzine Hydrochloride tablets available to the healthcare market, expanding its portfolio of generic central nervous system and antihistamine medications. The company listed the 10 mg, 25 mg, and 50 mg strengths of the tablet formulation with a market entry date of mid-January. This commercial availability followed the company's strategy to bolster its supply chain and offer a wider range of therapeutic options to patients and providers. The tablets are indicated for the symptomatic relief of anxiety and tension, as well as for the management of pruritus due to allergic conditions such as chronic urticaria and atopic dermatitis.

Key Market Players

• R-Biopharm AG
• Teva Pharmaceutical Industries Ltd
• Sun Pharmaceutical Industries Ltd
• GSK plc
• bioMerieux S.A.
• Danaher Corporation
• Thermo Fisher Scientific, Inc
• Siemens Healthcare AG
• AbbVie Inc.
• Pfizer Inc.

By Dosage Form	By Indication Type	By Region
Tablets Capsules Injection Syrup	Histamine-mediated pruritus Utricaria Atopic contact dermatitis	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Hydroxyzine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Hydroxyzine Market, By Dosage Form:

• Tablets
• Capsules
• Injection
• Syrup

• Hydroxyzine Market, By Indication Type:

• Histamine-mediated pruritus
• Utricaria
• Atopic contact dermatitis

• Hydroxyzine Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE